Recital 5, Directive (EU) 2002/98

In forcecited 3×

In order to ensure that there is an equivalent level of safety and quality of blood components, whatever their intended purpose, technical requirements for the collection and testing of all blood and blood components including starting materials for medicinal products should be established by this Directive. Directive 2001/83/EC should be amended accordingly.

  • Judgment of the Court (First Chamber), 13 March 2014. Octapharma France SAS v Agence nationale de sécurité du médicament et des produits de Decision

    Recitals 2, 3, and 5 in the preamble to Directive 2002/98 state: The availability of blood and blood components used for therapeutic purposes is dependent largely on Community citizens who are prepared to donate. In order to safeguard …

    13 Mar 2014 · 62012CJ0512

  • Opinion of Advocate General Mengozzi delivered on 17 July 2014. Geoffrey Léger v Ministre des Affaires sociales, de la Santé et des Droits dDecision

    Its adoption is part of a context in which the Member States had previously experienced failings in their systems for monitoring and securing the transfusion chain. Consequently, the supranational authorities took up the matter, at the …

    17 Jul 2014 · 62013CC0528

  • Opinion of Advocate General Jääskinen delivered on 7 November 2013. Octapharma France SAS v Agence nationale de sécurité du médicament et deDecision

    Recital 4 of Directive 2002/98 recalls that Directive 2001/83 refers to measures to be taken by Member States to prevent the transmission of infectious diseases in respect of blood or blood components as a starting point for the …

    7 Nov 2013 · 62012CC0512